Orchid forays into non-antibiotic generic formulations seg

Published on Fri, Jun 15, 2007 at 14:10 |  Source : Moneycontrol.com

Updated at Fri, Jun 15, 2007 at 16:33  

19004 Investors following Orchid Chemical. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

ALSO READ

The Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Ltd (Orchid) today announced that it has received the tentative approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Terbinafine HCL 250 mg Tablets. This is the first ANDA approval received by the company in the non-penicillin, non-cephalosporin (NPNC) space.

 

Terbinafine is the AB-rated generic equivalent of Novartis's Lamisil Tablets. An anti-fungal molecule, Terbinafine has a current US retail market size of USD 650 million. Orchid plans to launch this product in the US market through its distribution partner, Actavis upon patent expiry on June 30, 2007.

 

"We are happy about our first non-antibiotic product approval. Based on this timely approval, we would be launching the product in the US and hope to garner a good market share and revenues given the market standing of our distribution partner, Actavis . Though, the non-antibiotic space is relatively more crowded than the antibiotic product space, we are focusing on a niche product basket involving stringent development and manufacturing challenges which would help in a better market presence", said Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.

 

Sourced From: Orchid Chemicals & Pharmaceuticals Ltd  

  

Trending News

Business News

Sony to roll-out ICS update next week, Xperia PLAY gets the boot
Reebok execs named in Rs 870 cr fraud denied anticipatory bail "Reebok execs named in Rs 870 cr fraud denied anticipatory bail"

Live Updates: KKR favourites in last-over battle

Rel Comm Q4 Cons Net Revenue Up 5% At `5,310 Cr (QoQ)

The latest earning numbers FIRST on CNBC-TV18
Videos

May 25 2012, 22:26

NHPC posts profit amid capacity addition, delay woes

- in Results Boardroom

Interviews

May 27 2012, 11:52 | Source: CNBC-TV18

Expect to maintain EBIDTA margin ahead: Wockhardt  

May 27 2012, 11:00 | Source: CNBC-TV18

e-commerce market in India: What's in store?  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!